MDSpire - Summary
Feature

Advancing Precision Oncology: What Pooled Trial Data Reveal About 177 Lu-PSMA-617 in mCRPC

Radiopharmaceutical therapy is rapidly reshaping the treatment landscape for advanced prostate cancer.

  • March 31, 2026

  • 3 min

Share

Radiopharmaceutical therapy with 177Lu-PSMA-617 is transforming advanced prostate cancer treatment. During the 2026 ASTRO Radiopharmaceutical Symposium, investigators revealed results from a pooled analysis of Phase II and III trials showing this therapy helps delay disease progression in metastatic castration-resistant prostate cancer (mCRPC). Involving over 2,500 patients across seven trials, the analysis demonstrated a 36% reduced risk of disease progression. However, the overall survival benefit was inconsistent, highlighting the need for careful patient selection and multidisciplinary care to maximize treatment impact.

Original Source(s)

Advancing Precision Oncology: What Pooled Trial Data Reveal About 177 Lu-PSMA-617 in mCRPC

  • March 31, 2026

Related Content

‘Prostate Screening Saved My Life’—Is That Really True in Most Cases?

Prostate specific antigen (PSA) screening remains one of the most controversial of “standard” medical practices. As recently as the 2026 Super Bowl, one of the more unusual TV advertisements, sponsore...

Adjuvant Pembrolizumab Plus Belzutifan in Patients With RCC at Increased Risk of Recurrence

“Adjuvant pembrolizumab plus belzutifan demonstrated a statistically significant and clinically meaningful improvement in disease-free survival vs pembrolizumab plus placebo in patients with clear cel...

It's Like PCR, But Better

Geoff Smith introduces the mcPCR method for methylated DNA analysis that is expanding the potential of epigenetics for disease detection